(Q35558558)

8 August 2017

1 reference

title

EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer (English)

1 reference

8 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00662-2

21 March 2024

2

L. Biganzoli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556916

21 March 2024

Pierre-Louis Soubeyran

5

object named as

P. Soubeyran

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556916

21 March 2024

author name string

Tjan-Heijnen VC

6

1 reference

8 August 2017

L. Repetto

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556916

21 March 2024

C. H. Koehne

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556916

21 March 2024

A. S. Luebbe

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556916

21 March 2024

V. C G. Tjan-Heijnen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556916

21 March 2024

M. S. Aapro

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556916

21 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14556916

21 March 2024

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S0959804903006622?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00662-2

https://api.elsevier.com/content/article/PII:S0959804903006622?httpAccept=text/plain

21 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00662-2

European Journal of Cancer

21 March 2024

published in

1 reference

8 August 2017

volume

39

1 reference

8 August 2017

issue

16

1 reference

8 August 2017

page(s)

2264-2272

1 reference

Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

A case for geriatric oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Aging and marrow neutrophil reserves

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Dose-intensive chemotherapy in extensive-stage small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Ran

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Effect of recombinant human granulocyte colony stimulating factor (lenograstim) on chemotherapy induced neutropenia in patients with urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900662-2

7 January 2021

General guidelines for the management of older patients with cancer

1

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00662-2

Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma

21 March 2024

7

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00662-2

Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma

21 March 2024

19

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00662-2

Intensified M-VEC chemotherapy with G-CSF support as outpatient treatment for advanced bladder cancer

21 March 2024

44

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00662-2

21 March 2024

Identifiers

1 reference

release_4bskk7ptsvhs5ofrlbugjrjljy

8 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4bskk7ptsvhs5ofrlbugjrjljy

24 November 2022

mapped directly with Wikidata item

1 reference